Definium Therapeutics Q1 2026: cash $373.4M; three Phase 3 readouts for DT120 ODT expected in coming months

Definium Therapeutics, Inc.

2026-Q1 EPS reported -$0.71 vs consensus -$0.50 ▼ miss (-41.4%)

Cash and investments $373.4M as of March 31, 2026; expected to fund operations into 2028.
R&D expenses $41.5M (up $18.1M YoY) driven by DT120 ODT program costs; G&A $17.7M (up $8.9M).
Three Phase 3 topline data readouts for DT120 ODT anticipated: Emerge (MDD) late Q2 2026, Voyage (GAD) early Q3, Panorama (GAD) late Q3.
DT120 ODT program expanded into PTSD; Phase 3 Haven study expected to initiate in 2027 with ~200 patients.
Ascend (MDD) trial first patient dosing expected Q2 2026; enrollment complete in Emerge and Voyage.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Definium Therapeutics, Inc. reported financial results for fiscal quarter ended March 31, 2026.

Period: fiscal quarter ended March 31, 2026
Result: reported results

Exact text from the filing

On May 7, 2026, Definium Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for its fiscal quarter ended March 31, 2026, as well as information regarding a conference call to discuss these financial results and the Company’s recent corporate highlights.

View on SEC.gov

Browse all earnings releases →

Definium Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-211929

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.